Application of combined pharmaco-physiotherapy to relief clinical symptomatics and improve quality of life in patients with dry eye syndrome

Aim: To evaluate the effects of a therapeutic regimen incorporating magnetophoresis with Argensept and tear replacement therapy on patient complaints, clinical symptoms, and quality of life in individuals with mild to moderate dry eye syndrome (DES). Materials and methods: The study included 50 individuals (100 eyes) diagnosed with mild to moderate DES (H04.1 according to the International Classification of Diseases, 10th revision). The average patient age was 43.3 years. Participants were divided into two groups. The first group (comparison group) comprised 25 patients (50 eyes) who received a therapeutic regimen consisting of magnetophoresis with Argensept and tear replacement therapy. The second group (control group) included 25 patients (50 eyes) who received only tear replacement therapy. Additionally, data from 20 healthy individuals (40 eyes) were used as a reference for normal values. All participants underwent Schirmer’s test and completed the OSDI (Ocular Surface Disease Index) questionnaire before and after treatment. Results: Following treatment, the group receiving the combined therapy of magnetophoresis with Argensept and tear replacement therapy demonstrated a significant reduction in the frequency of complaints and clinical symptoms. Additionally, highly significant improvements were observed in Schirmer’s test scores and OSDI questionnaire results in patients with both mild and moderate DES. Conclusion: The application of a therapeutic regimen that includes magnetophoresis with Argensept and tear replacement therapy significantly reduces complaints, improves subjective well-being, and enhances the quality of life in patients with mild to moderate DES. These findings are supported by improvements in Schirmer’s test scores and OSDI questionnaire responses.